<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911517</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-NCRTPD</org_study_id>
    <nct_id>NCT04911517</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.</brief_title>
  <official_title>Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hangzhou New Horizon Health Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beigene (Beijing) Biotechnology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Tianjin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long course radiotherapy plus neoadjuvant chemotherapy followed by resection total mesorecta&#xD;
      excision has accepted widespread recognized in the treatment of locally advanced rectal&#xD;
      cancer (LARC). Tislelizumab, an anti-PD1(programmed death 1) humanized IgG4 (Immunoglomin G4)&#xD;
      monoclonal antibody, has been demonstrated with clinical activity and is approved for&#xD;
      treating recurrent/refractory classical Hodgkin lymphoma and locally advanced/metastatic&#xD;
      urothelial carcinoma in China.&#xD;
&#xD;
      The aim of This NCRT-PD-1-LARC trial is to evaluate the efficacy and safety of long course&#xD;
      neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorecta excision for&#xD;
      LARC. This NCRT-PD-1-LARC trial will be a prospective, multicenter and phase Ⅱ clinical trial&#xD;
      designed to evaluate the safety and efficacy of LARC patients treated with long course&#xD;
      neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorecta excision. It will&#xD;
      consecutively enroll 50 stage II/III LARC patients (cT3N0M0 and cT1-3N1-2M0) with the tumor&#xD;
      distal location ≤ 10cm from anal verge at 7 centers in China. The enrolled patients will&#xD;
      receive long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles&#xD;
      capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg,&#xD;
      iv.gtt, day8), followed by total mesorecta excision 6-8 week after the end of radiotherapy.&#xD;
      The primary efficacy endpoint will be the pathological complete response (pCR) rate, which is&#xD;
      defined as absence of viable tumor cells in the primary tumor and lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The enrolled patients in this NCRT-PD-1-LARC trial will receive long course radiotherapy (50 Gy/25 f, 2 Gy/f, 5 days/week) and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day8), followed by total mesorecta excision 6-8 week after the end of radiotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response（pCR）</measure>
    <time_frame>1 year</time_frame>
    <description>All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neoadjuvant rectal (NAR) score</measure>
    <time_frame>1 year</time_frame>
    <description>The neoadjuvant rectal (NAR) score is a promising indicator of survival after preoperative chemoradiotherapy for rectal cancer. The NAR score was calculated according to the following formula: NAR score = [5pN - 3(cT - pT) + 12]2∕9.61. (clinical tumor (cT) stage, pathologic tumor (pT) stage, pathologic nodal (pN) stage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>ORR is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORR rate is the sum of complete response (CR) and partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 year</time_frame>
    <description>During the surgical process, the surgeon will evaluate the level of cancer resection. It will be classified as R0, R1, R2 resection. Therefore, we can calculate R0 resection rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anal preservation rate</measure>
    <time_frame>1 year</time_frame>
    <description>the surgeon will decide whether the anal can be preserved on the basis of the rectal cancer and intraoperative situation. anal preservation rate is the percentage of patients who achieve anal preservation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year local recurrence rate (LRR)</measure>
    <time_frame>3 year</time_frame>
    <description>During the 3-year follow-up, the percentage of local recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival (DFS)</measure>
    <time_frame>3 year</time_frame>
    <description>During the 3-year follow-up, the percentage of the patients who is disease free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival (OS)</measure>
    <time_frame>3 year</time_frame>
    <description>During the 3-year follow-up, the percentage of the patients who is sill survival at the end of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations</intervention_name>
    <description>long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer</description>
    <arm_group_label>long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients have been fully aware of the content of this study and signed the informed&#xD;
             consent voluntarily;&#xD;
&#xD;
          -  Patients with rectal cancers must satisfied all the following conditions: Stage II/III&#xD;
             LARC (cT1-3N1-2M0)；Tumor distal location ≤10 cm from anal verge (MRI diagnosed);&#xD;
&#xD;
          -  Patients regardless of gender with aged ≥18 years and ECOG score of 0 or 1;&#xD;
&#xD;
          -  Physical and viscera function of patients can withstand major abdominal surgery;&#xD;
&#xD;
          -  Patients are willing and able to follow the study protocol during the study;&#xD;
&#xD;
          -  Patients give consent to the use of blood and pathological specimens for study;&#xD;
&#xD;
          -  Within 28 days prior to enrolment, we must confirm a negative serological pregnancy&#xD;
             test for child-bearing age women and they agree to use effective contraception for the&#xD;
             duration of drug use and for 60 days after the last dose.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients have a present or previous active malignancy except the diagnosis of rectal&#xD;
             cancer this time;&#xD;
&#xD;
          -  Patients underwent major surgery within 4 weeks prior to study treatment;&#xD;
&#xD;
          -  Patients have any condition affects the absorption of capecitabine through&#xD;
             gastrointestinal tract;&#xD;
&#xD;
          -  Patients have severe uncontrolled recurrent infections, or other severe uncontrolled&#xD;
             concomitant diseases;&#xD;
&#xD;
          -  Patients who are allergic to any of the ingredients under study;&#xD;
&#xD;
          -  Patients with severe concomitant diseases with estimated survival ≤ 5 years;&#xD;
&#xD;
          -  Patients with present or previous moderate or severe liver and kidney damage presently&#xD;
             or previously;&#xD;
&#xD;
          -  Patients have received other study medications or any immunotherapy currently or in&#xD;
             the past;&#xD;
&#xD;
          -  Patients preparing for or previously received organ or bone marrow transplant;&#xD;
&#xD;
          -  Patients who received immunosuppressive or systemic hormone therapy for&#xD;
             immunosuppressive purposes within 1 month prior to the initiation of study therapy;&#xD;
&#xD;
          -  Patients with congenital or acquired immune deficiency (such as HIV infection);&#xD;
&#xD;
          -  If patients with a history of uncontrolled epilepsy, central nervous system disease or&#xD;
             mental disorder, the investigator will determine whether the clinical severity&#xD;
             prevents the signing of informed consent or affects the patient's oral medication&#xD;
             compliance;&#xD;
&#xD;
          -  Patients with other factors that may affect the study results or cause the study to be&#xD;
             terminated midway, such as alcoholism, drug abuse, other serious diseases (including&#xD;
             mental illness) requiring combined treatment and severe laboratory examination&#xD;
             abnormalities.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yaohongwei@ccmu.edu.cn Yao, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of General Surgery, Beijing Friendship Hospital, Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongwei Yao, Dr.</last_name>
    <phone>+8613611015609</phone>
    <phone_ext>63139203</phone_ext>
    <email>yaohongwei@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005 Aug 20;23(24):5620-7. Epub 2005 Jul 11.</citation>
    <PMID>16009958</PMID>
  </reference>
  <reference>
    <citation>Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006 Oct 1;24(28):4620-5.</citation>
    <PMID>17008704</PMID>
  </reference>
  <reference>
    <citation>Hata T, Takahashi H, Sakai D, Haraguchi N, Nishimura J, Kudo T, Chu M, Takemasa I, Taroh S, Mizushima T, Doki Y, Mori M. Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer. Surg Today. 2017 Nov;47(11):1372-1377. doi: 10.1007/s00595-017-1527-5. Epub 2017 May 4.</citation>
    <PMID>28474202</PMID>
  </reference>
  <reference>
    <citation>Shamseddine A, Zeidan YH, El Husseini Z, Kreidieh M, Al Darazi M, Turfa R, Kattan J, Khalifeh I, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Jamali F, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Charafeddine M, Geara F. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. Radiat Oncol. 2020 Oct 7;15(1):233. doi: 10.1186/s13014-020-01673-6.</citation>
    <PMID>33028346</PMID>
  </reference>
  <reference>
    <citation>Shen Z, Bu Z, Li A, Lu J, Zhu L, Chong CS, Gao Z, Jiang K, Wang S, Li F, Xiao Y, Ji J, Ye Y. Multicenter study of surgical and oncologic outcomes of extra-levator versus conventional abdominoperineal excision for lower rectal cancer. Eur J Surg Oncol. 2020 Jan;46(1):115-122. doi: 10.1016/j.ejso.2019.08.017. Epub 2019 Aug 21.</citation>
    <PMID>31471089</PMID>
  </reference>
  <reference>
    <citation>Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer. 2021 Jan 1;12(2):417-427. doi: 10.7150/jca.48337. eCollection 2021. Review.</citation>
    <PMID>33391438</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Chen WZ, Chen XD, Ma LL, Zhang FM, Lin J, Zhuang CL, Yu Z, Chen XL, Chen XX. Impact of Visceral Obesity and Sarcopenia on Short-Term Outcomes After Colorectal Cancer Surgery. Dig Dis Sci. 2018 Jun;63(6):1620-1630. doi: 10.1007/s10620-018-5019-2. Epub 2018 Mar 16.</citation>
    <PMID>29549473</PMID>
  </reference>
  <reference>
    <citation>Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP, Hochhauser D, Hull MA, Koelzer VH, McNair AGK, Monahan KJ, Näthke I, Norton C, Novelli MR, Steele RJC, Thomas AL, Wilde LM, Wilson RH, Tomlinson I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut. 2018 Jan;67(1):179-193. doi: 10.1136/gutjnl-2017-315333. Review.</citation>
    <PMID>29233930</PMID>
  </reference>
  <reference>
    <citation>Sung JJY, Chiu HM, Jung KW, Jun JK, Sekiguchi M, Matsuda T, Kyaw MH. Increasing Trend in Young-Onset Colorectal Cancer in Asia: More Cancers in Men and More Rectal Cancers. Am J Gastroenterol. 2019 Feb;114(2):322-329. doi: 10.14309/ajg.0000000000000133.</citation>
    <PMID>30694865</PMID>
  </reference>
  <reference>
    <citation>Cao Y, Li W, Wang Z, Pang H. Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori. 2021 Aug;107(4):282-291. doi: 10.1177/0300891620940382. Epub 2020 Jul 31. Review.</citation>
    <PMID>32734832</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Programmed Cell Death 1 Receptor</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>2025.5-</ipd_time_frame>
    <ipd_access_criteria>via reasonable email requests</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

